Concepedia

Robert Iannone

RI

Statistics

Publications

29

Citations

5.7K

H-Index

23

Active since

1992

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Dana-Farber Cancer Institute

Moffitt Cancer Center

Institut Gustave Roussy

Fred Hutch Cancer Center

Robert Iannone is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, radiation oncology, and oncology.

Top concepts

Publications per year

1992–2025

29

Publications

29

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Caroline Robert, Antoni Ribas, Jedd D. Wolchok et al. · The Lancet · 2014 · 1.7K citations

, , +10

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

Aditya Bardia, Ingrid A. Mayer, Linda T. Vahdat et al. · New England Journal of Medicine · 2019 · 815 citations

Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

Amita Patnaik, Soonmo Peter Kang, Drew Rasco et al. · Clinical Cancer Research · 2015 · 767 citations

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

Shahneen Sandhu, William R. Schelman, George Wilding et al. · The Lancet Oncology · 2013 · 551 citations

, , +7

Durable engraftment of major histocompatibility complex–incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide

Leo Luznik, Sanju Jalla, Laura Engstrom et al. · Blood · 2001 · 335 citations · Full text

1–5 of 29